Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Accolade, Inc.
  6. Summary
    ACCD   US00437E1029

ACCOLADE, INC.

(ACCD)
  Report
Delayed Nasdaq  -  04:00:00 2023-05-26 pm EDT
11.52 USD   +2.77%
05/24BofA Upgrades Accolade to Buy From Neutral, Price Target is $16.50
MT
05/23APIs & IP Protection
AQ
05/09Transcript : Accolade, Inc. Presents at Bank of America Securities 2023 Healthcare Conference, May-09-2023 03:40 PM
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2023 05/23/2023 05/24/2023 05/25/2023 05/26/2023 Date
11.05(c) 11.08(c) 11.91(c) 11.21(c) 11.52(c) Last
560 472 530 207 996 509 577 669 531 228 Volume
+2.13% +0.27% +7.49% -5.88% +2.77% Change
More quotes
Estimated financial data (e) (USD)
Sales 2024 410 M - -
Net income 2024 -133 M - -
Net cash position 2024 154 M - -
P/E ratio 2024 -6,57x
Yield 2024 -
Sales 2025 491 M - -
Net income 2025 -117 M - -
Net cash position 2025 155 M - -
P/E ratio 2025 -7,35x
Yield 2025 -
Capitalization 848 M 848 M -
EV / Sales 2024 1,69x
EV / Sales 2025 1,41x
Nbr of Employees 2 370
Free-Float 93,7%
More Financials
Company
Accolade, Inc. is a provider of personalized, technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The Company’s customers are primarily employers that contract with Accolade to provide their employees and their employees’ families (the members) a single place to turn for their health, healthcare, and benefits needs. It also offers... 
Read more
More about the company
Ratings of Accolade, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ACCOLADE, INC.
05/24BofA Upgrades Accolade to Buy From Neutral, Price Target is $16.50
MT
05/23APIs & IP Protection
AQ
05/09Transcript : Accolade, Inc. Presents at Bank of America Securities 2023 Healt..
CI
05/09Accolade : Webcast Analyst Day Full Deck Presentation
PU
05/09Accolade : Capital Markets Day Supplemental Deck
PU
05/08Transcript : Accolade, Inc. - Analyst/Investor Day
CI
05/08Accolade Announces Upcoming Investor Events
AQ
05/01DA Davidson Raises Accolade's Price Target to $16 From $14, Keeps Buy Rating
MT
04/28Guggenheim Adjusts Accolade's Price Target to $18 From $16, Keeps Buy Rating
MT
04/28Canaccord Genuity Adjusts Price Target on Accolade to $18 From $14, Maintains Buy Ratin..
MT
04/28Morgan Stanley Adjusts Accolade's Price Target to $14 From $11, Keeps Equalweight Ratin..
MT
04/28ACCOLADE, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
04/27Accolade : Fiscal Q4 Earnings Snapshot
AQ
04/27Transcript : Accolade, Inc., Q4 2023 Earnings Call, Apr 27, 2023
CI
04/27Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2023 
GL
More news
News in other languages on ACCOLADE, INC.
04/27Accolade, Inc. donne des prévisions de résultats pour le premier trimestre fiscal se te..
04/27Accolade, Inc. annonce ses résultats pour le quatrième trimestre et l'exercice clos le ..
03/23Les actions d'Accolade augmentent après la révision à la hausse de Guggenheim
03/06Accolade et Lyra Health s'associent pour soutenir les soins de santé comportementale de..
02/28Accolade, Inc. Réitère ses prévisions de revenus pour le quatrième trimestre fiscal se ..
More news
Analyst Recommendations on ACCOLADE, INC.
More recommendations
ETFs positioned on ACCOLADE, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
SPDR S&P Health Care Services ETF - USD1.48%-2.95%United_States
IShares Micro-Cap ETF - USD0.16%-0.54%United_States
IShares Russell 2000 Value ETF - USD0.06%0.07%United_States
Vanguard Russell 2000 Value ETF - USD0.06%-0.03%United_States
BMO MSCI Genomic Innovation Index ETF - CAD0.04%0.00%-NC
More ETFs positioned on ACCOLADE, INC.
Chart ACCOLADE, INC.
Duration : Period :
Accolade, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACCOLADE, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 11,52 $
Average target price 15,53 $
Spread / Average Target 34,8%
EPS Revisions
Managers and Directors
Rajeev Singh Chairman & Chief Executive Officer
Robert N. Cavanaugh President
Stephen H. Barnes Chief Financial Officer
Shantanu Nundy Chief Medical Officer
Drew Garner Executive Vice President-Engineering
Sector and Competitors
1st jan.Capi. (M$)
ACCOLADE, INC.47.88%848
CVS HEALTH CORPORATION-27.42%86 716
HCA HEALTHCARE, INC.10.19%72 736
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY23.75%25 491
LABORATORY CORPORATION OF AMERICA HOLDINGS-8.44%19 102
QUEST DIAGNOSTICS INCORPORATED-14.49%14 983
-40% off: Our subscriptions help you unlock hidden opportunities!
Subscribe
fermer